Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
With this fully revised fourth edition, Dr Stahl returns to the essential roots of what it means to become a neurobiologically empowered psychopharmacologist, expertly guided in the selection and combination of treatments for individual patients in practice. Embracing the unifying themes of 'symptom endophenotypes', dimensions of psychopathology that cut across syndromes, and 'symptoms and circuits', every aspect of the text has been updated to the frontiers of current knowledge, with the clarity of explanation and illustration that only Dr Stahl can bring. Integrating much of the basic neuroscience into the clinical chapters, and with major additions in the areas of psychosis, antipsychotics, antidepressants, impulsivity, compulsivity and addiction, this is the single most readily readable source of information on disease and drug mechanisms. This remains the essential text for all students and professionals in mental health seeking to understand and utilize current therapeutics, and to anticipate the future for novel medications.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Transporters receptors and enzymes as targets of psychopharmacological drug action
Ion channels as targets of psychopharmacological drug action
Psychosis and schizophrenia
Anxiety disorders and anxiolytics
Other editions - View all
5HT2A receptors acetylcholine acid activity ADHD agents Alzheimer’s disease amygdala amyloid antagonism antagonist antidepressant actions anxiety disorders aripiprazole atypical antipsychotics autoreceptors axon behavior benzodiazepines bipolar disorder block brain circuits bupropion calcium channels cause cell cholinergic chronic clinical clozapine cognitive conventional antipsychotic D2 receptors dementia discussed in Chapter dopamine dopamine pathway dopamine release doses efﬁcacy enhance enzyme ﬁrst full agonist function GABA GABAA receptors gene glutamate glycine histamine hypnotics hypothetically impulsivity increased inhibition insomnia interneurons ion channels kinase levels ligands major depressive mania MAO-A MAOIs mechanism of action mesolimbic monoamine mood stabilizers neuron neurotransmitter nicotine NMDA receptors norepinephrine normal nucleus accumbens opioid orexin pain partial agonist patients pharmacologic positive symptoms postsynaptic potential prefrontal cortex presynaptic protein psychiatric psychosis psychotic quetiapine receptors Figure reduce regulate reuptake inhibitors risk schizophrenia SERT side effects signal transduction sleep SNRI sodium speciﬁc spectrum SSRIs stimulation striatum subtypes subunits synapse target therapeutic transporter trazodone treatment VSCCs